menu

What Echo Aspects are Essential to PH Diagnosis?

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Advancing Diagnosis and Risk Assessment in PH

What Echo Aspects are Essential to PH Diagnosis?

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.75 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including cardiologists, pulmonologists, echocardiographers, sonographers, nurse practitioners and other clinicians involved in the management of patients with pulmonary hypertension.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Gain an understanding of the new guidelines and algorithms developed to detect PH early in the community
    • Identify appropriate circumstances to implement 3 or 4 strata risk assessments.
    • Enable early recognition of sub-populations of patients who are at high risk and identify appropriate screening candidates
  • Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
     
    This activity was planned by and for the healthcare team, and learners will receive 1.75 Interprofessional Continuing Education (IPCE) credits for learning and change.

  • Faculty Disclosure of Commercial Relationships

    Disclosure Policy
    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Richard Channick, MD, chair for this educational event, receives research funds from Altavant, Aerovate, Respira, and Merck; and receives consulting fees from Altavant, Aerovate, Respira, and Merck.

    Jean Elwing, MD, chair for this educational event, receives research funds from United Therapeutics, Gossamer Bio, Bayer, Acceleron/Merck, Altavant, Aerovate, Pharmosa, Janssen and Lung LLC; and receives consulting fees from United Therapeutics, Gossamer Bio, Bayer, Acceleron/Merck, Altavant, Aerovate, Pharmosa, Janssen and Lung LLC.

    Dinesh Khanna, MD, MS, chair for this educational event, receives research funds from Boehringer Ingelheim, BMS, Bayer and Pfizer; and receives consulting fees from Astra Zeneca, Boehringer Ingelheim, BMS, Chemomab, Horizon, Prometheus, Janssen and UCB.

    Martha Kingman, FNP-C, DNP, chair for this educational event, receives consulting fees from Janssen, Liquidia, Aerovate, Aerami, Merck and Gossamer. 

    Richard Krasuski, MD, chair for this educational event, receives research funds from Actelion/Janssen, Artivion, Adult Congenital Heart Association, Corvia, Edwards Lifesciences and Medtronic; and receives consulting fees from Actelion/Janssen, Bayer, W.L Gore, Medtronic and Neptune Medical. 

    Vallerie V. McLaughlin, MD, chair for this educational event, receives research funds from Aerovate, Altavant, Gossamer-Bio, Janssen, Merck and Sonovie; and receives consulting fees from  Aerami, Aerovate,  Altavant, Bayer, Caremark, L.L.C., Corvista, Gossamer Bio, Janssen, Merck and United Therapeutics.

    Sudarshan Rajagopal, MD, PhD, chair for this educational event, receives research funds from Janssen, United Therapeutics and Altavant; receives royalties and is a patent holder for Polarean; receives consulting fees from Aerami, Altavant, GossamerBio, Insmed, Janssen, Liquidia, Polarean, United Therapeutics and Visterra; and has ownership interest in Apie Therapeutics. 

    Rajan Saggar MD, chair for this educational event, receives consulting fees from Janssen, Aerovate, United Therapeutics, Third Pole and Aria.

    Oksana A. Shlobin, MD, chair for this educational event, receives consulting fees from UT, Janssen, Bayer, Altavant, Aerami, Aerovate and Merck. 

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    Dixon W. Wilde, PhD, FAHA, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by independent educational grants from Actelion Pharmaceuticals US, Division of Janssen Pharmaceuticals and United Therapeutics Corporation.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 5/31/23 through 5/31/24, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule19 Apr 2024